December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Biogen

< Previous 1 2 3 Next >
Biogen Celebrates 40 Years as a Pioneer in Neuroscience
Biogen (Nasdaq:BIIB): 
Tickers BIIB
From Business Wire News Releases
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab 
Tickers BIIB
From Business Wire News Releases
New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants
New SPINRAZA® (nusinersen) Data Unveiled at AAN Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants 
Tickers BIIB IONS
From Business Wire News Releases
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases 
Tickers BIIB IONS
From Business Wire News Releases
Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
Biogen Builds on its 40-Year Legacy in Neuroscience with Presentation of Research From its Portfolio of Medicines and Investigational Programs 
Tickers BIIB
From Business Wire News Releases
Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD)... 
Tickers BIIB
From Business Wire News Releases
New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)
New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen) 
Tickers BIIB IONS
From Business Wire News Releases
Biogen to Present at the Cowen and Company 38th Annual Health Care Conference
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 38th Annual Health Care Conference. The webcast will be live on Monday, March 12, 2018 at 3:30 p.m. ET. To... 
Tickers BIIB
From Business Wire News Releases
The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy 
Tickers BIIB IONS
From Business Wire News Releases
Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Biogen reports topline results from Phase 2b study of natalizumab in acute ischemic stroke 
Tickers BIIB
From Business Wire News Releases
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
BIOGEN TO REPORT FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS ON JANUARY 25, 2018- UPDATED CALL TIMING 
Tickers BIIB
From Business Wire News Releases
Biogen Foundation Commits $10 Million to STEM Education in Cambridge and Somerville
Biogen Foundation Commits $10 Million to STEM Education in Cambridge and Somerville 
From Business Wire News Releases
Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY 
Tickers BIIB IONS
From Business Wire News Releases
Biogen Appoints Mark Hernon as SVP, Chief Information Officer
Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4. 
Tickers BIIB
From Business Wire News Releases
Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
Biogen (Nasdaq:BIIB) and Alkermes plc (Nasdaq:ALKS) today announced that they have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral,... 
Tickers ALKS BIIB
From Business Wire News Releases
Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer
Biogen (Nasdaq: BIIB) announced today the appointment of Jeffrey D. Capello as Executive Vice President and Chief Financial Officer effective as of December 11, 2017. 
Tickers BIIB
From Business Wire News Releases
Biogen Appoints Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation
Biogen (Nasdaq: BIIB) announced today the appointment of Chirfi Guindo as Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation. 
Tickers BIIB
From Business Wire News Releases
Biogen Presents New Data from Long-Term Extension of Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
BIOGEN PRESENTS NEW DATA FROM LONG-TERM EXTENSION OF PHASE 1B STUDY OF INVESTIGATIONAL ALZHEIMER’S DISEASE TREATMENT ADUCANUMAB 
Tickers BIIB
From Business Wire News Releases
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy 
Tickers BIIB IONS
From Business Wire News Releases
Biogen and Ionis Win Prestigious Prix Galien Award for SPINRAZA as Best Biotechnology Product
Biogen and Ionis have been awarded the prestigious 2017 Prix Galien USA Award for Best Biotechnology Product for SPINRAZA® (nusinersen). 
Tickers BIIB
From Business Wire News Releases
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis
Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis 
Tickers BIIB
From Business Wire News Releases
Biogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive Approach
Biogen (NASDAQ: BIIB) confirms its comprehensive approach to tackle MS at the seventh joint meeting of ECTRIMS/ACTRIMS. 
Tickers BIIB
From Business Wire News Releases
Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
Biogen’s SPINRAZA® Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with SMA. 
Tickers BIIB IONS
From Business Wire News Releases
Biogen Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
Biogen (NASDAQ: BIIB) announced the appointment of Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective today. 
Tickers BIIB
From Business Wire News Releases
Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
Biogen (NASDAQ: BIIB) announced today the appointment of Dr. Sanjay Jariwala as Senior Vice President, Worldwide Medical. 
Tickers BIIB
From Business Wire News Releases
Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
Biogen (NASDAQ: BIIB) today announced results from a recently conducted analysis of the long-term extension (LTE) of its ongoing Phase 1b study of aducanumab, the company’s investigational treatment... 
Tickers BIIB
From Business Wire News Releases
IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is Approved in the European Union
IMRALDI®, BIOGEN’S ADALIMUMAB BIOSIMILAR REFERENCING HUMIRA®, IS APPROVED IN THE EUROPEAN UNION 
Tickers BIIB
From Business Wire News Releases
Biogen Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Medicinal Sciences
Biogen (NASDAQ:BIIB) today announced the appointment of Anabella Villalobos, Ph.D., as senior vice president, Biotherapeutic & Medicinal Sciences (BTMS). Dr. Villalobos will lead Biogen’s BTMS... 
Tickers BIIB
From Business Wire News Releases
Alisha A. Alaimo Appointed SVP of Biogen’s US Therapeutic Operations
Biogen (NASDAQ: BIIB) announced today the appointment of Alisha A. Alaimo to Senior Vice President of US Therapeutic Operations, where she will lead sales and marketing, market access, patient services... 
Tickers BIIB
From Business Wire News Releases
Biogen to Present Data at Alzheimer's Association International Conference® 2017 (AAIC®)
Biogen (NASDAQ: BIIB) will present data from its Alzheimer’s disease programs at the Alzheimer's Association International Conference® 2017 (AAIC®) in London, July 16 - 20, 2017. 
Tickers BIIB
From Business Wire News Releases
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.